BioSpace News Archive

StimGuard LLC, a privately-held medical device company engaged in the development, manufacture and pre-commercialization of innovative wireless, injectable electroceutical device solutions for urological conditions, announced that it is changing its corporate name to Micron Medical Corporation.

Celltrion Group announced its successful transition to the second phase of development for an antiviral treatment to fight the novel coronavirus pandemic, following the completion of the first phase of securing 300 different types of antibodies that bind to the antigen last month.

Getinge announces a partnership with the international organization WaterAid.

To provide global vision and opportunities for the intelligent coordination between pharmaceutical enterprises and logistics service and equipment suppliers, P-Logi China 2020, organized by Informa Markets and CCCMHPIE and co-organized by Sinoexpo Informa Markets

TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that Alfonso Quintás Cardama, M.D., Chief Medical Officer of TCR 2 Therapeutics, will present an update on company progress during the panel “Emergence of TCRs and Next-Generation Therapies” at the Goldman Sachs Cell Therapy Day on April 6, 2020 at 2:00pm

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company, has learnt that buy recommendations and letters are being circulated in Germany. The Company, along with the Federal Financial Supervisory Authority of Germany (“BaFin”) suggests shareholders fully understand these materials. BaFin advises all investors to check the information given in the buy recommendations by consulting sources, especially if the buy recom

A world-renowned leader in infectious disease and transfusion medicine research, Vitalant Research Institute (VRI)—a division of Vitalant, the nation’s largest independent blood service provider—is helping direct collection and processing of blood plasma donations from recovered COVID-19 patients and developing technologies to det

AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 111,750 shares of the company’s common stock to eight new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635.

Global Blood Therapeutics, Inc. announced that on April 1, 2020, the compensation committee of GBT’s board of directors granted three new employees restricted stock units for an aggregate of 10,550 shares of the company’s common stock.

Assure Holdings Corp., a provider of intraoperative neuromonitoring services, announced updates resulting from rapidly changing market conditions driven by the novel coronavirus pandemic.